rheumatoid arthritis (RA) and biosimilars Archives

Abstract Number: 553 • ACR/ARP Annual Meeting 2019
Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study
Marc Schmalzing¹, Ayman Askari ², David Walsh ³, Maria Carmen Castro ⁴, Francisco J. De Toro ⁵, Slawomir Jeka ⁶, Herbert Kellner ⁷, Hilke Friccius-Quecke ⁸, Fabricio Furlan ⁸, Sohaib Hachaichi ⁸ and Tom Sheeran ⁹, ¹Universitätsklinikum Würzburg, Department of Rheumatology/ Clinical Immunology, Wuerzburg, Germany, ²Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry, England, United Kingdom, ³Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵University Hospital A Coruña, A Coruña, Spain, ⁶University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁷Praxis Prof. Herbert Kellner, Munich, Germany, ⁸Hexal AG, a Sandoz company, Holzkirchen, Germany, ⁹Cannock and Wolverhampton Hospitals, Staffordshire, United Kingdom
Background/Purpose: GP2015 is an etanercept biosimilar approved for moderate to severely active rheumatoid arthritis (RA), severe active ankylosing spondylitis (AS), and active and progressive psoriatic…

Abstracts tagged "rheumatoid arthritis (RA) and biosimilars"